This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of ureter
C3_URETER
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
109 |
4. Check minimum number of eventsNone |
109 |
5. Include endpointsNone |
109 |
6. Filter based on genotype QC (FinnGen only) |
102 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of ureter
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of ureter, including Hilmo
- Malignant neoplasm of urinary organs
- Malignant neoplasm of urinary organs, including Hilmo
- Solid cancers
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 102 | 35 | 67 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.03 |
| Median age at first event (years) | 74.38 | 73.79 | 74.68 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 109
- Matched controls
- 1090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8120/3-C66.9
ICD-O-3
Transitional cell carcinoma, NOS, of ureter
+∞
116.5
90
*
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
116.5
90
*
UKC02
NOMESCO Finland
Cystoscopy
71.3
89.8
98
121
R31
ICD-10 Finland
Unspecified haematuria
25.0
67.8
74
85
UKB02
NOMESCO Finland
Retrograde ureteroscopy
797.3
52.0
47
*
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
47.4
42
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
46.2
41
*
130
Kela drug reimbursment
Malignant tumour
+∞
42.5
38
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
112.0
40.5
42
6
JN4AD
NOMESCO Finland
Body CT examination
16.5
39.7
40
37
KCD02
NOMESCO Finland
Transurethral resection of bladder
276.1
38.5
37
*
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
34.2
31
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
34.2
31
*
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
33.0
30
*
Z51.5
ICD-10 Finland
Palliative care
15.3
32.7
33
30
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
60.8
27.3
31
7
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
177.3
27.0
27
*
H02AB02
ATC
dexamethasone; systemic
160.3
24.7
25
*
TPH07
NOMESCO Finland
Cathetrisation of artery
7.9
21.9
38
69
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
21.6
20
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
9.4
19.6
27
37
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
19.3
18
*
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
54.5
19.1
22
5
A04AA02
ATC
granisetron; systemic, transdermal
+∞
18.2
17
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
18.2
17
*
B01AB10
ATC
tinzaparin; parenteral
8.4
18.0
27
41
JN3AD
NOMESCO Finland
Abdominal CT examination
7.3
17.9
32
59
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
75.8
17.4
19
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
17.3
35
73
KH1AD
NOMESCO Finland
CT of urinary organs
18.5
16.9
26
18
WZC00
NOMESCO Finland
Treatment plan or consultation
5.3
16.4
49
145
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
99.8
16.1
17
*
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
+∞
16.0
15
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.4
15.4
31
64
WX402
NOMESCO Finland
General anaesthesia
5.4
14.6
38
99
WX302
NOMESCO Finland
Thoracal epidural anesthesy
19.6
14.1
21
13
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
+∞
13.8
13
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.9
13.8
41
119
XX3DW
NOMESCO Finland
Time consuming IT work
14.2
13.6
23
20
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
12.7
12
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
13.5
12.7
22
20
WF049
NOMESCO Finland
Radiotherapy of metastasis
146.1
12.7
13
*
WZC30
NOMESCO Finland
Teaching
5.2
12.4
31
77
N02AA05
ATC
oxycodone; systemic
4.7
12.1
36
103
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.4
12.0
41
131
A04AA01
ATC
ondansetron; systemic, rectal
17.7
11.8
18
12
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
11.7
11
*
KBJ10
NOMESCO Finland
Cutaneous ureteroenterostomy
+∞
11.7
11
*
TKC20
NOMESCO Finland
Catheterisation of bladder
6.1
11.6
23
46
J01MA02
ATC
ciprofloxacin; systemic
4.0
11.3
67
313
B01AB05
ATC
enoxaparin; parenteral
3.9
11.1
53
213
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
10.6
10
*
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
+∞
10.6
10
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
10.6
10
*
KBD00
NOMESCO Finland
Partial excision of ureter
+∞
10.6
10
*
JN4BD
NOMESCO Finland
Extensive body CT
9.0
10.0
21
28
ZXE20
NOMESCO Finland
More than three and less than five hours
4.5
9.8
28
77
JN4CD
NOMESCO Finland
Very extensive body CT
19.8
9.7
14
8
KC1GB
NOMESCO Finland
Cystography with X-ray
109.1
9.6
10
*
KBB00
NOMESCO Finland
Biopsy of ureter
+∞
9.5
9
*
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
9.5
9
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
15.6
9.5
15
11
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
40.3
9.2
11
*
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
40.3
9.2
11
*
ZXE00
NOMESCO Finland
One hour or less
3.4
8.9
56
261
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
54.5
8.8
10
*
KBH20
NOMESCO Finland
Replantation of ureter
97.3
8.5
9
*
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
8.4
8
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
14.5
8.1
13
10
ZXE10
NOMESCO Finland
More than one and less than three hours
3.1
7.8
51
240
XKD00
NOMESCO Finland
Uroflowmetry
3.4
7.7
35
132
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
85.7
7.5
8
*
KCW96
NOMESCO Finland
Other operations on bladder
85.7
7.5
8
*
A79
ICPC
Malignancy NOS
+∞
7.4
7
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
7.4
7
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
7.4
7
*
WF002
NOMESCO Finland
Radical radiotherapy
74.0
6.5
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.1
6.4
33
133
J01MA12
ATC
levofloxacin; systemic
3.2
6.4
32
127
J01EA01
ATC
trimethoprim; systemic
3.0
6.3
38
167
KA3EB
NOMESCO Finland
Antegrade pyelography
+∞
6.3
6
*
KA3GB
NOMESCO Finland
Retrograde pyelography
+∞
6.3
6
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
6.3
6
*
KBV00
NOMESCO Finland
Insertion of stent into ureter
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
6.3
6
*
A04AD12
ATC
aprepitant; systemic
+∞
6.3
6
*
L03AA02
ATC
filgrastim; parenteral
+∞
6.3
6
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
R82.8
ICD-10 Finland
Abnormal findings on cytological and histological examination of urine
+∞
6.3
6
*
ZX136
NOMESCO Finland
Intravesicalis
+∞
6.3
6
*
KCC10
NOMESCO Finland
Cystoprostatectomy
+∞
6.3
6
*
8130/2-C66.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of ureter
+∞
6.3
6
*
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Urology
34 [38004474]
34 [38004474]
1.1e+00
3.4e+00
5.4e+00
1.0e+50
5.7e+00
5.5e+00
4.2e+00
cases:22.02%
controls:8.26%
cases:51.38%
controls:3.39%
cases:58.72%
controls:0.64%
cases:44.04%
controls:0.00%
cases:58.76%
controls:0.46%
cases:91.01%
controls:3.96%
cases:88.24%
controls:9.78%
24
90
85
1000
56
37
53
1053
64
7
45
1083
48
0
61
1090
57
5
40
1083
81
42
8
1018
45
81
6
747
Cystoscopy
UKC02 [2001306005]
UKC02 [2001306005]
1.9e+00
4.1e+00
—
1.0e+50
1.0e+50
6.0e+00
4.9e+00
cases:20.18%
controls:3.49%
cases:40.37%
controls:1.10%
—
—
cases:6.42%
controls:0.00%
cases:10.31%
controls:0.00%
cases:74.16%
controls:0.66%
cases:80.39%
controls:3.02%
22
38
87
1052
44
12
65
1078
—
7
0
102
1090
10
0
87
1088
66
7
23
1053
41
25
10
803
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
4.4e-01
2.1e+00
4.0e+00
—
3.0e+00
1.9e+00
2.0e+00
cases:17.43%
controls:11.93%
cases:33.03%
controls:5.69%
cases:23.85%
controls:0.55%
—
—
cases:14.43%
controls:0.83%
cases:33.71%
controls:6.89%
cases:56.86%
controls:14.86%
19
130
90
960
36
62
73
1028
26
6
83
1084
—
14
9
83
1079
30
73
59
987
29
123
22
705
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
5.7e-01
2.2e+00
3.9e+00
—
3.4e+00
1.8e+00
1.7e+00
cases:15.60%
controls:9.45%
cases:31.19%
controls:4.68%
cases:22.02%
controls:0.55%
—
—
cases:14.43%
controls:0.55%
cases:30.34%
controls:6.42%
cases:49.02%
controls:15.58%
17
103
92
987
34
51
75
1039
24
6
85
1084
—
14
6
83
1082
27
68
62
992
25
129
26
699
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
5.6e-01
2.2e+00
3.8e+00
—
3.3e+00
1.8e+00
1.5e+00
cases:16.51%
controls:10.18%
cases:33.03%
controls:5.41%
cases:22.02%
controls:0.64%
—
—
cases:15.46%
controls:0.64%
cases:32.58%
controls:7.17%
cases:49.02%
controls:18.24%
18
111
91
979
36
59
73
1031
24
7
85
1083
—
15
7
82
1081
29
76
60
984
25
151
26
677
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
3.7e-01
2.0e+00
3.8e+00
—
3.4e+00
1.7e+00
1.5e+00
cases:11.01%
controls:7.89%
cases:23.85%
controls:4.04%
cases:20.18%
controls:0.55%
—
—
cases:12.37%
controls:0.46%
cases:24.72%
controls:5.47%
cases:43.14%
controls:14.01%
12
86
97
1004
26
44
83
1046
22
6
87
1084
—
12
5
85
1083
22
58
67
1002
22
116
29
712
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
6.0e-01
1.9e+00
3.6e+00
—
3.4e+00
2.2e+00
1.2e+00
cases:13.76%
controls:8.07%
cases:25.69%
controls:4.86%
cases:21.10%
controls:0.73%
—
—
cases:16.49%
controls:0.64%
cases:34.83%
controls:5.57%
cases:37.25%
controls:14.73%
15
88
94
1002
28
53
81
1037
23
8
86
1082
—
16
7
81
1081
31
59
58
1001
19
122
32
706
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
4.8e-01
1.8e+00
3.9e+00
—
3.1e+00
1.8e+00
1.5e+00
cases:33.03%
controls:23.39%
cases:45.87%
controls:12.66%
cases:43.12%
controls:1.56%
—
—
cases:24.74%
controls:1.47%
cases:48.31%
controls:13.49%
cases:66.67%
controls:31.28%
36
255
73
835
50
138
59
952
47
17
62
1073
—
24
16
73
1072
43
143
46
917
34
259
17
569
Outpatient Hospital
22 [8756]
22 [8756]
8.4e-02
1.1e+00
3.4e+00
1.0e+50
3.6e+00
1.9e+00
1.4e+00
cases:30.28%
controls:28.53%
cases:20.18%
controls:8.07%
cases:16.51%
controls:0.64%
cases:8.26%
controls:0.00%
cases:19.59%
controls:0.64%
cases:34.83%
controls:7.26%
cases:45.10%
controls:16.30%
33
311
76
779
22
88
87
1002
18
7
91
1083
9
0
100
1090
19
7
78
1081
31
77
58
983
23
135
28
693
Unspecified haematuria
R31 [45553726]
R31 [45553726]
2.2e+00
4.4e+00
—
1.0e+50
1.0e+50
3.0e+00
1.8e+00
cases:13.76%
controls:1.74%
cases:37.61%
controls:0.73%
—
—
cases:7.34%
controls:0.00%
cases:12.37%
controls:0.00%
cases:14.61%
controls:0.85%
cases:13.73%
controls:2.54%
15
19
94
1071
41
8
68
1082
—
8
0
101
1090
12
0
85
1088
13
9
76
1051
7
21
44
807
Cytology report of Urine Cyto stain
47525-1 [3049717]
47525-1 [3049717]
2.6e+00
4.2e+00
—
1.0e+50
1.0e+50
—
4.4e+00
cases:11.93%
controls:1.01%
cases:27.52%
controls:0.55%
—
—
cases:6.42%
controls:0.00%
cases:5.15%
controls:0.00%
—
—
cases:52.94%
controls:1.33%
13
11
96
1079
30
6
79
1084
—
7
0
102
1090
5
0
92
1088
—
27
11
24
817
Outpatient Visit
OP [9202]
OP [9202]
2.7e-01
4.0e-01
1.7e+00
3.8e+00
1.9e+00
2.3e+00
2.0e+00
cases:84.40%
controls:80.46%
cases:72.48%
controls:63.76%
cases:42.20%
controls:11.65%
cases:29.36%
controls:0.92%
cases:42.27%
controls:9.83%
cases:94.38%
controls:63.58%
cases:98.04%
controls:86.84%
92
877
17
213
79
695
30
395
46
127
63
963
32
10
77
1080
41
107
56
981
84
674
5
386
50
719
1
109
Inpatient Hospital
21 [8717]
21 [8717]
5.2e-02
1.1e+00
2.6e+00
1.0e+50
2.8e+00
1.4e+00
1.1e+00
cases:35.78%
controls:34.59%
cases:28.44%
controls:11.83%
cases:20.18%
controls:1.83%
cases:10.09%
controls:0.00%
cases:20.62%
controls:1.56%
cases:34.83%
controls:11.98%
cases:47.06%
controls:22.46%
39
377
70
713
31
129
78
961
22
20
87
1070
11
0
98
1090
20
17
77
1071
31
127
58
933
24
186
27
642
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
5.1e-02
7.6e-01
2.3e+00
3.5e+00
2.3e+00
4.2e-01
-5.0e-02
cases:51.38%
controls:50.09%
cases:57.80%
controls:38.99%
cases:47.71%
controls:8.44%
cases:13.76%
controls:0.46%
cases:43.30%
controls:6.80%
cases:56.18%
controls:45.66%
cases:68.63%
controls:69.69%
56
546
53
544
63
425
46
665
52
92
57
998
15
5
94
1085
42
74
55
1014
50
484
39
576
35
577
16
251
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
2.7e-01
1.4e+00
3.2e+00
—
2.2e+00
1.1e+00
1.1e+00
cases:14.68%
controls:11.56%
cases:22.02%
controls:6.70%
cases:11.93%
controls:0.55%
—
—
cases:8.25%
controls:1.01%
cases:17.98%
controls:6.79%
cases:43.14%
controls:20.65%
16
126
93
964
24
73
85
1017
13
6
96
1084
—
8
11
89
1077
16
72
73
988
22
171
29
657
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
53292-9 [3041096]
3.7e-01
1.8e+00
2.8e+00
—
3.0e+00
1.3e+00
8.1e-01
cases:11.93%
controls:8.53%
cases:17.43%
controls:3.39%
cases:8.26%
controls:0.55%
—
—
cases:8.25%
controls:0.46%
cases:15.73%
controls:4.72%
cases:23.53%
controls:12.08%
13
93
96
997
19
37
90
1053
9
6
100
1084
—
8
5
89
1083
14
50
75
1010
12
100
39
728
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
1.7e-01
1.2e+00
2.3e+00
—
2.5e+00
1.7e+00
1.1e+00
cases:14.68%
controls:12.66%
cases:21.10%
controls:7.52%
cases:5.50%
controls:0.55%
—
—
cases:8.25%
controls:0.74%
cases:29.21%
controls:6.89%
cases:41.18%
controls:18.96%
16
138
93
952
23
82
86
1008
6
6
103
1084
—
8
8
89
1080
26
73
63
987
21
157
30
671
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
5.0e-01
1.5e+00
2.9e+00
—
2.9e+00
1.5e+00
9.5e-01
cases:33.94%
controls:23.76%
cases:37.61%
controls:11.47%
cases:24.77%
controls:1.74%
—
—
cases:20.62%
controls:1.47%
cases:41.57%
controls:13.77%
cases:56.86%
controls:33.70%
37
259
72
831
41
125
68
965
27
19
82
1071
—
20
16
77
1072
37
146
52
914
29
279
22
549
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
3.4e-01
1.8e+00
3.9e+00
—
—
1.5e+00
1.6e+00
cases:10.09%
controls:7.43%
cases:20.18%
controls:3.85%
cases:18.35%
controls:0.46%
—
—
—
—
cases:20.22%
controls:5.28%
cases:39.22%
controls:11.96%
11
81
98
1009
22
42
87
1048
20
5
89
1085
—
—
18
56
71
1004
20
99
31
729
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
3.7e-02
7.3e-01
2.3e+00
3.5e+00
2.3e+00
4.2e-01
-6.1e-02
cases:51.38%
controls:50.46%
cases:57.80%
controls:39.82%
cases:47.71%
controls:8.62%
cases:12.84%
controls:0.46%
cases:43.30%
controls:7.17%
cases:56.18%
controls:45.75%
cases:68.63%
controls:69.93%
56
550
53
540
63
434
46
656
52
94
57
996
14
5
95
1085
42
78
55
1010
50
485
39
575
35
579
16
249
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
5.0e-01
2.2e+00
—
1.0e+50
2.7e+00
1.9e+00
1.8e+00
cases:13.76%
controls:8.81%
cases:15.60%
controls:2.02%
—
—
cases:17.43%
controls:0.00%
cases:6.19%
controls:0.46%
cases:17.98%
controls:3.11%
cases:31.37%
controls:6.88%
15
96
94
994
17
22
92
1068
—
19
0
90
1090
6
5
91
1083
16
33
73
1027
16
57
35
771
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
-1.3e-01
1.5e+00
3.0e+00
—
2.3e+00
1.7e+00
6.8e-01
cases:9.17%
controls:10.28%
cases:18.35%
controls:4.86%
cases:10.09%
controls:0.55%
—
—
cases:7.22%
controls:0.74%
cases:22.47%
controls:5.00%
cases:25.49%
controls:14.73%
10
112
99
978
20
53
89
1037
11
6
98
1084
—
7
8
90
1080
20
53
69
1007
13
122
38
706
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
5.2e-02
7.8e-01
2.2e+00
3.2e+00
2.3e+00
4.2e-01
-1.6e-01
cases:54.13%
controls:52.84%
cases:63.30%
controls:44.13%
cases:51.38%
controls:10.55%
cases:13.76%
controls:0.64%
cases:48.45%
controls:8.27%
cases:60.67%
controls:50.28%
cases:68.63%
controls:71.98%
59
576
50
514
69
481
40
609
56
115
53
975
15
7
94
1083
47
90
50
998
54
533
35
527
35
596
16
232
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
7.7e-02
7.4e-01
2.4e+00
2.9e+00
2.4e+00
4.1e-01
4.6e-02
cases:54.13%
controls:52.20%
cases:60.55%
controls:42.29%
cases:54.13%
controls:9.63%
cases:11.01%
controls:0.64%
cases:49.48%
controls:8.09%
cases:59.55%
controls:49.43%
cases:72.55%
controls:71.62%
59
569
50
521
66
461
43
629
59
105
50
985
12
7
97
1083
48
88
49
1000
53
524
36
536
37
593
14
235
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
1.1e-02
5.8e-01
2.1e+00
4.5e+00
1.9e+00
2.1e-01
-1.3e-02
cases:55.96%
controls:55.69%
cases:65.14%
controls:51.19%
cases:62.39%
controls:17.16%
cases:44.95%
controls:0.92%
cases:55.67%
controls:15.90%
cases:62.92%
controls:58.02%
cases:74.51%
controls:74.76%
61
607
48
483
71
558
38
532
68
187
41
903
49
10
60
1080
54
173
43
915
56
615
33
445
38
619
13
209
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
5.2e-02
7.9e-01
2.2e+00
3.0e+00
2.4e+00
4.3e-01
-1.7e-01
cases:54.13%
controls:52.84%
cases:63.30%
controls:43.85%
cases:51.38%
controls:10.55%
cases:11.93%
controls:0.64%
cases:48.45%
controls:8.18%
cases:60.67%
controls:50.00%
cases:68.63%
controls:72.10%
59
576
50
514
69
478
40
612
56
115
53
975
13
7
96
1083
47
89
50
999
54
530
35
530
35
597
16
231
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
5.5e-02
7.8e-01
2.2e+00
3.0e+00
2.3e+00
4.3e-01
-1.7e-01
cases:54.13%
controls:52.75%
cases:63.30%
controls:44.04%
cases:51.38%
controls:10.46%
cases:11.93%
controls:0.64%
cases:48.45%
controls:8.27%
cases:60.67%
controls:50.19%
cases:68.63%
controls:72.10%
59
575
50
515
69
480
40
610
56
114
53
976
13
7
96
1083
47
90
50
998
54
532
35
528
35
597
16
231
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
5.2e-02
7.8e-01
2.2e+00
3.0e+00
2.3e+00
4.3e-01
-1.7e-01
cases:54.13%
controls:52.84%
cases:63.30%
controls:44.04%
cases:51.38%
controls:10.55%
cases:11.93%
controls:0.64%
cases:48.45%
controls:8.27%
cases:60.67%
controls:50.09%
cases:68.63%
controls:72.10%
59
576
50
514
69
480
40
610
56
115
53
975
13
7
96
1083
47
90
50
998
54
531
35
529
35
597
16
231
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
5.2e-02
7.8e-01
2.2e+00
3.0e+00
2.3e+00
4.3e-01
-1.6e-01
cases:54.13%
controls:52.84%
cases:63.30%
controls:44.13%
cases:51.38%
controls:10.55%
cases:11.93%
controls:0.64%
cases:48.45%
controls:8.27%
cases:60.67%
controls:50.09%
cases:68.63%
controls:71.98%
59
576
50
514
69
481
40
609
56
115
53
975
13
7
96
1083
47
90
50
998
54
531
35
529
35
596
16
232
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
4.8e-02
7.8e-01
2.2e+00
3.0e+00
2.4e+00
4.3e-01
-1.7e-01
cases:54.13%
controls:52.94%
cases:63.30%
controls:44.22%
cases:51.38%
controls:10.64%
cases:11.93%
controls:0.64%
cases:48.45%
controls:8.18%
cases:60.67%
controls:50.00%
cases:68.63%
controls:72.10%
59
577
50
513
69
482
40
608
56
116
53
974
13
7
96
1083
47
89
50
999
54
530
35
530
35
597
16
231
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
5.2e-02
7.8e-01
2.2e+00
3.0e+00
2.3e+00
4.2e-01
-1.7e-01
cases:54.13%
controls:52.84%
cases:63.30%
controls:44.22%
cases:51.38%
controls:10.55%
cases:11.93%
controls:0.64%
cases:48.45%
controls:8.27%
cases:60.67%
controls:50.28%
cases:68.63%
controls:72.10%
59
576
50
514
69
482
40
608
56
115
53
975
13
7
96
1083
47
90
50
998
54
533
35
527
35
597
16
231
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
2.0e-01
1.5e+00
2.9e+00
—
2.5e+00
1.3e+00
8.6e-01
cases:18.35%
controls:15.50%
cases:30.28%
controls:8.99%
cases:15.60%
controls:1.01%
—
—
cases:12.37%
controls:1.19%
cases:29.21%
controls:9.72%
cases:49.02%
controls:28.86%
20
169
89
921
33
98
76
992
17
11
92
1079
—
12
13
85
1075
26
103
63
957
25
239
26
589
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
1.8e-01
1.5e+00
2.9e+00
—
2.3e+00
1.4e+00
9.4e-01
cases:18.35%
controls:15.78%
cases:30.28%
controls:9.17%
cases:15.60%
controls:1.01%
—
—
cases:11.34%
controls:1.29%
cases:29.21%
controls:9.53%
cases:50.98%
controls:28.86%
20
172
89
918
33
100
76
990
17
11
92
1079
—
11
14
86
1074
26
101
63
959
26
239
25
589
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
1.6e-01
1.4e+00
2.9e+00
—
2.3e+00
1.4e+00
8.9e-01
cases:17.43%
controls:15.23%
cases:28.44%
controls:8.99%
cases:15.60%
controls:1.01%
—
—
cases:11.34%
controls:1.29%
cases:29.21%
controls:9.53%
cases:49.02%
controls:28.38%
19
166
90
924
31
98
78
992
17
11
92
1079
—
11
14
86
1074
26
101
63
959
25
235
26
593
General Surgery
2 [38004447]
2 [38004447]
-6.0e-02
1.0e+00
3.2e+00
—
2.8e+00
2.0e+00
9.7e-01
cases:18.35%
controls:19.27%
cases:14.68%
controls:5.96%
cases:11.93%
controls:0.55%
—
—
cases:9.28%
controls:0.64%
cases:25.84%
controls:4.62%
cases:27.45%
controls:12.56%
20
210
89
880
16
65
93
1025
13
6
96
1084
—
9
7
88
1081
23
49
66
1011
14
104
37
724
Inpatient Visit
IP [9201]
IP [9201]
5.0e-01
1.5e+00
2.3e+00
1.0e+50
—
2.5e+00
1.3e+00
cases:11.93%
controls:7.61%
cases:18.35%
controls:4.59%
cases:4.59%
controls:0.46%
cases:20.18%
controls:0.00%
—
—
cases:33.71%
controls:3.87%
cases:39.22%
controls:15.22%
13
83
96
1007
20
50
89
1040
5
5
104
1085
22
0
87
1090
—
30
41
59
1019
20
126
31
702
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
-4.6e-02
1.4e+00
2.8e+00
—
2.2e+00
1.2e+00
9.5e-01
cases:13.76%
controls:14.31%
cases:22.94%
controls:6.61%
cases:11.93%
controls:0.83%
—
—
cases:9.28%
controls:1.10%
cases:21.35%
controls:7.26%
cases:39.22%
controls:19.93%
15
156
94
934
25
72
84
1018
13
9
96
1081
—
9
12
88
1076
19
77
70
983
20
165
31
663
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
2.0e-01
1.0e+00
2.5e+00
1.0e+50
3.0e+00
1.2e+00
6.1e-01
cases:23.85%
controls:20.37%
cases:22.94%
controls:9.91%
cases:15.60%
controls:1.47%
cases:7.34%
controls:0.00%
cases:11.34%
controls:0.64%
cases:28.09%
controls:10.94%
cases:41.18%
controls:27.54%
26
222
83
868
25
108
84
982
17
16
92
1074
8
0
101
1090
11
7
86
1081
25
116
64
944
21
228
30
600
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
2.2e-01
1.3e+00
3.6e+00
—
—
2.2e+00
8.8e-01
cases:13.76%
controls:11.38%
cases:17.43%
controls:5.69%
cases:22.02%
controls:0.73%
—
—
—
—
cases:30.34%
controls:4.72%
cases:29.41%
controls:14.73%
15
124
94
966
19
62
90
1028
24
8
85
1082
—
—
27
50
62
1010
15
122
36
706
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
-1.0e-01
1.3e+00
2.3e+00
—
—
2.0e+00
1.3e+00
cases:11.93%
controls:13.03%
cases:15.60%
controls:4.68%
cases:5.50%
controls:0.55%
—
—
—
—
cases:23.60%
controls:3.96%
cases:35.29%
controls:12.44%
13
142
96
948
17
51
92
1039
6
6
103
1084
—
—
21
42
68
1018
18
103
33
725
Acute tubulo-interstitial nephritis
N10 [45543856]
N10 [45543856]
1.3e+00
2.7e+00
—
—
—
2.5e+00
1.7e+00
cases:5.50%
controls:1.56%
cases:9.17%
controls:0.64%
—
—
—
—
—
—
cases:6.74%
controls:0.57%
cases:19.61%
controls:4.11%
6
17
103
1073
10
7
99
1083
—
—
—
6
6
83
1054
10
34
41
794
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
4.6e-02
4.6e-01
1.8e+00
3.0e+00
2.1e+00
3.2e-01
-1.2e-01
cases:33.03%
controls:32.02%
cases:37.61%
controls:27.61%
cases:31.19%
controls:6.79%
cases:10.09%
controls:0.55%
cases:30.93%
controls:5.24%
cases:38.20%
controls:31.04%
cases:45.10%
controls:48.07%
36
349
73
741
41
301
68
789
34
74
75
1016
11
6
98
1084
30
57
67
1031
34
329
55
731
23
398
28
430
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
—
1.6e+00
—
—
—
3.7e+00
3.2e+00
—
—
cases:4.59%
controls:0.92%
—
—
—
—
—
—
cases:16.85%
controls:0.47%
cases:29.41%
controls:1.69%
—
5
10
104
1080
—
—
—
15
5
74
1055
15
14
36
814
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
6.8e-01
2.5e+00
—
—
—
2.2e+00
1.8e+00
cases:11.93%
controls:6.42%
cases:17.43%
controls:1.65%
—
—
—
—
—
—
cases:21.35%
controls:2.83%
cases:35.29%
controls:8.09%
13
70
96
1020
19
18
90
1072
—
—
—
19
30
70
1030
18
67
33
761
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
—
1.9e+00
—
—
—
2.9e+00
1.7e+00
—
—
cases:6.42%
controls:1.01%
—
—
—
—
—
—
cases:11.24%
controls:0.66%
cases:15.69%
controls:3.26%
—
7
11
102
1079
—
—
—
10
7
79
1053
8
27
43
801
Emergency Room Visit
ER [9203]
ER [9203]
3.9e-03
9.4e-01
2.1e+00
—
1.9e+00
1.4e+00
7.0e-01
cases:38.53%
controls:38.44%
cases:31.19%
controls:15.05%
cases:15.60%
controls:2.11%
—
—
cases:8.25%
controls:1.29%
cases:37.08%
controls:12.64%
cases:49.02%
controls:32.25%
42
419
67
671
34
164
75
926
17
23
92
1067
—
8
14
89
1074
33
134
56
926
25
267
26
561
Emergency Medicine
93 [38004510]
93 [38004510]
1.3e-02
9.1e-01
2.6e+00
—
1.9e+00
8.9e-01
-1.7e-01
cases:17.43%
controls:17.25%
cases:23.85%
controls:11.19%
cases:12.84%
controls:1.10%
—
—
cases:7.22%
controls:1.10%
cases:25.84%
controls:12.55%
cases:29.41%
controls:32.97%
19
188
90
902
26
122
83
968
14
12
95
1078
—
7
12
90
1076
23
133
66
927
15
273
36
555
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.4e-01
9.5e-01
1.9e+00
—
2.4e+00
8.8e-01
8.2e-02
cases:44.04%
controls:40.64%
cases:45.87%
controls:24.77%
cases:28.44%
controls:5.50%
—
—
cases:34.02%
controls:4.32%
cases:49.44%
controls:28.87%
cases:56.86%
controls:54.83%
48
443
61
647
50
270
59
820
31
60
78
1030
—
33
47
64
1041
44
306
45
754
29
454
22
374
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
6.0e-02
8.7e-01
2.0e+00
—
3.0e+00
1.1e+00
8.8e-01
cases:14.68%
controls:13.94%
cases:13.76%
controls:6.24%
cases:7.34%
controls:1.01%
—
—
cases:11.34%
controls:0.64%
cases:21.35%
controls:7.92%
cases:37.25%
controls:19.69%
16
152
93
938
15
68
94
1022
8
11
101
1079
—
11
7
86
1081
19
84
70
976
19
163
32
665
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-1.1e-01
3.2e-01
1.5e+00
2.7e+00
1.9e+00
-2.0e-02
-1.5e-01
cases:36.70%
controls:39.27%
cases:36.70%
controls:29.72%
cases:25.69%
controls:7.06%
cases:7.34%
controls:0.55%
cases:27.84%
controls:5.33%
cases:32.58%
controls:33.02%
cases:49.02%
controls:52.78%
40
428
69
662
40
324
69
766
28
77
81
1013
8
6
101
1084
27
58
70
1030
29
350
60
710
25
437
26
391
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
5.8e-01
7.9e-01
2.5e+00
—
2.5e+00
1.1e+00
4.6e-01
cases:11.93%
controls:7.06%
cases:11.93%
controls:5.78%
cases:7.34%
controls:0.64%
—
—
cases:6.19%
controls:0.55%
cases:16.85%
controls:6.42%
cases:27.45%
controls:19.32%
13
77
96
1013
13
63
96
1027
8
7
101
1083
—
6
6
91
1082
15
68
74
992
14
160
37
668
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
2.3e-01
3.1e-02
2.5e+00
—
—
2.2e+00
1.2e+00
cases:15.60%
controls:12.84%
cases:6.42%
controls:6.24%
cases:5.50%
controls:0.46%
—
—
—
—
cases:31.46%
controls:5.00%
cases:35.29%
controls:14.01%
17
140
92
950
7
68
102
1022
6
5
103
1085
—
—
28
53
61
1007
18
116
33
712
Pathology report gross observation
24419-4 [3002256]
24419-4 [3002256]
1.1e+00
—
—
1.0e+50
—
3.3e+00
2.6e+00
cases:5.50%
controls:1.83%
—
—
—
—
cases:7.34%
controls:0.00%
—
—
cases:11.24%
controls:0.47%
cases:17.65%
controls:1.57%
6
20
103
1070
—
—
8
0
101
1090
—
10
5
79
1055
9
13
42
815
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
1.2e+00
2.6e+00
—
—
—
2.0e+00
1.2e+00
cases:18.35%
controls:6.51%
cases:18.35%
controls:1.65%
—
—
—
—
—
—
cases:15.73%
controls:2.55%
cases:21.57%
controls:7.61%
20
71
89
1019
20
18
89
1072
—
—
—
14
27
75
1033
11
63
40
765
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
2.6e-01
7.1e-01
2.4e+00
—
2.6e+00
4.7e-01
1.1e-01
cases:41.28%
controls:35.05%
cases:46.79%
controls:30.28%
cases:42.20%
controls:6.42%
—
—
cases:40.21%
controls:4.78%
cases:47.19%
controls:35.75%
cases:60.78%
controls:58.09%
45
382
64
708
51
330
58
760
46
70
63
1020
—
39
52
58
1036
42
379
47
681
31
481
20
347
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
5.1e-01
1.5e+00
1.0e+50
1.0e+50
—
3.2e+00
2.3e+00
cases:6.42%
controls:3.94%
cases:5.50%
controls:1.28%
cases:5.50%
controls:0.00%
cases:7.34%
controls:0.00%
—
—
cases:15.73%
controls:0.75%
cases:15.69%
controls:1.81%
7
43
102
1047
6
14
103
1076
6
0
103
1090
8
0
101
1090
—
14
8
75
1052
8
15
43
813
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
5.8e-01
2.1e+00
—
—
—
1.7e+00
1.4e+00
cases:11.93%
controls:7.06%
cases:15.60%
controls:2.20%
—
—
—
—
—
—
cases:14.61%
controls:2.92%
cases:23.53%
controls:6.88%
13
77
96
1013
17
24
92
1066
—
—
—
13
31
76
1029
12
57
39
771
Abdominal CT examination
JN3AD [2001305554]
JN3AD [2001305554]
—
2.2e+00
—
—
—
3.0e+00
1.2e+00
—
—
cases:6.42%
controls:0.73%
—
—
—
—
—
—
cases:10.11%
controls:0.57%
cases:9.80%
controls:3.02%
—
7
8
102
1082
—
—
—
9
6
80
1054
5
25
46
803
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
9.2e-02
7.4e-01
2.1e+00
—
2.3e+00
5.0e-01
-1.3e-01
cases:47.71%
controls:45.41%
cases:44.95%
controls:27.98%
cases:34.86%
controls:6.06%
—
—
cases:31.96%
controls:4.41%
cases:42.70%
controls:31.23%
cases:50.98%
controls:54.23%
52
495
57
595
49
305
60
785
38
66
71
1024
—
31
48
66
1040
38
331
51
729
26
449
25
379
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-7.0e-01
-3.3e-01
—
—
—
2.6e+00
2.4e+00
cases:14.68%
controls:25.69%
cases:5.50%
controls:7.52%
—
—
—
—
—
—
cases:13.48%
controls:1.13%
cases:21.57%
controls:2.42%
16
280
93
810
6
82
103
1008
—
—
—
12
12
77
1048
11
20
40
808
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
6.2e-01
7.6e-01
2.8e+00
—
—
2.2e+00
9.0e-01
cases:10.09%
controls:5.69%
cases:6.42%
controls:3.12%
cases:8.26%
controls:0.55%
—
—
—
—
cases:16.85%
controls:2.17%
cases:17.65%
controls:7.97%
11
62
98
1028
7
34
102
1056
9
6
100
1084
—
—
15
23
74
1037
9
66
42
762
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
3.4e-01
8.3e-01
2.8e+00
—
—
2.0e+00
1.0e+00
cases:11.01%
controls:8.07%
cases:8.26%
controls:3.76%
cases:8.26%
controls:0.55%
—
—
—
—
cases:19.10%
controls:3.11%
cases:23.53%
controls:9.90%
12
88
97
1002
9
41
100
1049
9
6
100
1084
—
—
17
33
72
1027
12
82
39
746
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
2.6e-01
7.1e-01
1.5e+00
—
1.9e+00
1.3e+00
8.3e-01
cases:31.19%
controls:25.87%
cases:23.85%
controls:13.30%
cases:9.17%
controls:2.29%
—
—
cases:14.43%
controls:2.39%
cases:39.33%
controls:15.57%
cases:54.90%
controls:34.66%
34
282
75
808
26
145
83
945
10
25
99
1065
—
14
26
83
1062
35
165
54
895
28
287
23
541
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
51484-4 [3030981]
—
2.6e+00
—
—
—
2.0e+00
1.5e+00
—
—
cases:8.26%
controls:0.64%
—
—
—
—
—
—
cases:7.87%
controls:1.13%
cases:15.69%
controls:3.86%
—
9
7
100
1083
—
—
—
7
12
82
1048
8
32
43
796
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
2.8e-01
8.8e-01
1.5e+00
—
1.3e+00
9.8e-01
7.1e-01
cases:22.94%
controls:18.35%
cases:22.02%
controls:10.46%
cases:14.68%
controls:3.76%
—
—
cases:12.37%
controls:3.77%
cases:24.72%
controls:10.94%
cases:39.22%
controls:24.15%
25
200
84
890
24
114
85
976
16
41
93
1049
—
12
41
85
1047
22
116
67
944
20
200
31
628
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
2.1e-01
1.4e+00
—
—
—
2.3e+00
2.2e+00
cases:5.50%
controls:4.50%
cases:4.59%
controls:1.19%
—
—
—
—
—
—
cases:10.11%
controls:1.13%
cases:11.76%
controls:1.45%
6
49
103
1041
5
13
104
1077
—
—
—
9
12
80
1048
6
12
45
816
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
5.4e-01
1.6e+00
—
—
2.8e+00
1.1e+00
1.2e+00
cases:6.42%
controls:3.85%
cases:14.68%
controls:3.21%
—
—
—
—
cases:7.22%
controls:0.46%
cases:11.24%
controls:4.06%
cases:23.53%
controls:8.70%
7
42
102
1048
16
35
93
1055
—
—
7
5
90
1083
10
43
79
1017
12
72
39
756
nitrofurantoin; oral
J01XE01 [21603058]
J01XE01 [21603058]
—
—
—
—
—
2.5e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.66%
cases:17.65%
controls:3.38%
—
—
—
—
—
7
7
82
1053
9
28
42
800
EKG study
11524-6 [3013512]
11524-6 [3013512]
1.6e-01
5.7e-01
2.1e+00
—
2.0e+00
9.3e-01
3.2e-01
cases:14.68%
controls:12.75%
cases:12.84%
controls:7.71%
cases:8.26%
controls:1.10%
—
—
cases:7.22%
controls:1.01%
cases:19.10%
controls:8.49%
cases:25.49%
controls:19.93%
16
139
93
951
14
84
95
1006
9
12
100
1078
—
7
11
90
1077
17
90
72
970
13
165
38
663
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
3.4e-01
1.5e+00
1.0e+50
—
—
2.5e+00
1.6e+00
cases:11.01%
controls:8.07%
cases:7.34%
controls:1.74%
cases:4.59%
controls:0.00%
—
—
—
—
cases:11.24%
controls:1.04%
cases:17.65%
controls:4.11%
12
88
97
1002
8
19
101
1071
5
0
104
1090
—
—
10
11
79
1049
9
34
42
794
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
4.7e-01
—
—
—
—
2.5e+00
1.5e+00
cases:8.26%
controls:5.32%
—
—
—
—
—
—
—
—
cases:14.61%
controls:1.32%
cases:21.57%
controls:5.92%
9
58
100
1032
—
—
—
—
13
14
76
1046
11
49
40
779
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
1.5e-01
1.1e+00
2.3e+00
—
—
1.6e+00
7.4e-01
cases:8.26%
controls:7.16%
cases:11.01%
controls:3.85%
cases:4.59%
controls:0.46%
—
—
—
—
cases:17.98%
controls:4.06%
cases:23.53%
controls:12.80%
9
78
100
1012
12
42
97
1048
5
5
104
1085
—
—
16
43
73
1017
12
106
39
722
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
—
—
—
—
—
3.7e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:15.73%
controls:0.47%
cases:11.76%
controls:2.05%
—
—
—
—
—
14
5
75
1055
6
17
45
811
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
—
1.9e+00
—
—
—
3.6e+00
1.8e+00
—
—
cases:4.59%
controls:0.73%
—
—
—
—
—
—
cases:20.22%
controls:0.66%
cases:11.76%
controls:2.05%
—
5
8
104
1082
—
—
—
18
7
71
1053
6
17
45
811
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
5.0e-02
5.9e-01
1.9e+00
—
1.6e+00
2.9e-01
-9.4e-02
cases:12.84%
controls:12.29%
cases:15.60%
controls:9.27%
cases:12.84%
controls:2.20%
—
—
cases:9.28%
controls:1.93%
cases:15.73%
controls:12.26%
cases:19.61%
controls:21.14%
14
134
95
956
17
101
92
989
14
24
95
1066
—
9
21
88
1067
14
130
75
930
10
175
41
653
trimethoprim; oral, parenteral
J01EA01 [21602931]
J01EA01 [21602931]
6.4e-01
1.5e+00
—
—
—
1.9e+00
1.2e+00
cases:10.09%
controls:5.60%
cases:11.01%
controls:2.66%
—
—
—
—
—
—
cases:16.85%
controls:2.83%
cases:23.53%
controls:8.21%
11
61
98
1029
12
29
97
1061
—
—
—
15
30
74
1030
12
68
39
760
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
8.0e-01
—
—
—
—
—
3.3e+00
cases:4.59%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
cases:25.49%
controls:1.21%
5
23
104
1067
—
—
—
—
—
13
10
38
818
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
-7.1e-02
6.9e-02
1.1e+00
-1.0e+50
1.1e+00
1.1e+00
1.4e-01
cases:43.12%
controls:44.86%
cases:28.44%
controls:27.06%
cases:16.51%
controls:6.15%
cases:0.00%
controls:0.55%
cases:17.53%
controls:6.43%
cases:55.06%
controls:29.62%
cases:56.86%
controls:53.38%
47
489
62
601
31
295
78
795
18
67
91
1023
0
6
109
1084
17
70
80
1018
49
314
40
746
29
442
22
386
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
-3.2e-01
1.7e+00
—
—
—
3.3e+00
8.8e-01
cases:4.59%
controls:6.24%
cases:6.42%
controls:1.19%
—
—
—
—
—
—
cases:25.84%
controls:1.32%
cases:13.73%
controls:6.16%
5
68
104
1022
7
13
102
1077
—
—
—
23
14
66
1046
7
51
44
777
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
—
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.73%
controls:0.72%
—
—
—
—
—
—
7
6
44
822
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
—
1.5e+00
—
—
—
3.0e+00
1.0e+00
—
—
cases:4.59%
controls:1.10%
—
—
—
—
—
—
cases:13.48%
controls:0.75%
cases:13.73%
controls:5.31%
—
5
12
104
1078
—
—
—
12
8
77
1052
7
44
44
784
dexamethasone; oral, parenteral
H02AB02 [21602730]
H02AB02 [21602730]
—
—
—
—
—
3.0e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:16.85%
controls:1.04%
cases:9.80%
controls:3.38%
—
—
—
—
—
15
11
74
1049
5
28
46
800
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
1.6e-01
1.7e+00
1.0e+50
—
—
2.9e+00
1.6e+00
cases:9.17%
controls:7.89%
cases:6.42%
controls:1.28%
cases:7.34%
controls:0.00%
—
—
—
—
cases:12.36%
controls:0.75%
cases:13.73%
controls:3.14%
10
86
99
1004
7
14
102
1076
8
0
101
1090
—
—
11
8
78
1052
7
26
44
802
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.47%
—
—
—
—
—
—
—
7
5
82
1055
—
Palliative care
Z51.5 [45547323]
Z51.5 [45547323]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:0.60%
—
—
—
—
—
—
5
5
46
823
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
4.2e-01
1.5e+00
—
—
—
1.1e+00
1.3e+00
cases:5.50%
controls:3.67%
cases:12.84%
controls:3.12%
—
—
—
—
—
—
cases:11.24%
controls:4.15%
cases:29.41%
controls:9.78%
6
40
103
1050
14
34
95
1056
—
—
—
10
44
79
1016
15
81
36
747
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-6.2e-02
3.3e-01
7.8e-01
2.0e+00
6.7e-01
3.5e-02
-4.5e-01
cases:76.15%
controls:77.25%
cases:77.98%
controls:71.74%
cases:49.54%
controls:31.01%
cases:13.76%
controls:2.02%
cases:47.42%
controls:31.53%
cases:75.28%
controls:74.62%
cases:84.31%
controls:89.37%
83
842
26
248
85
782
24
308
54
338
55
752
15
22
94
1068
46
343
51
745
67
791
22
269
43
740
8
88
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
2.7e-01
1.4e+00
1.0e+50
—
—
2.8e+00
1.5e+00
cases:9.17%
controls:7.16%
cases:5.50%
controls:1.38%
cases:5.50%
controls:0.00%
—
—
—
—
cases:12.36%
controls:0.85%
cases:13.73%
controls:3.38%
10
78
99
1012
6
15
103
1075
6
0
103
1090
—
—
11
9
78
1051
7
28
44
800
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
2.7e-01
1.3e+00
—
—
—
1.4e+00
8.1e-01
cases:10.09%
controls:7.89%
cases:11.93%
controls:3.49%
—
—
—
—
—
—
cases:13.48%
controls:3.58%
cases:21.57%
controls:10.87%
11
86
98
1004
13
38
96
1052
—
—
—
12
38
77
1022
11
90
40
738
Catheterisation of bladder
TKC20 [2001306020]
TKC20 [2001306020]
—
2.7e+00
—
—
—
—
—
—
—
cases:6.42%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
7
5
102
1085
—
—
—
—
—
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
I26.9 [45552785]
-1.0e+50
—
—
—
—
—
2.7e+00
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:0.72%
0
8
109
1082
—
—
—
—
—
5
6
46
822
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.73%
controls:1.21%
—
—
—
—
—
—
7
10
44
818
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
59275-8 [40762366]
—
-1.0e+50
—
1.0e+50
—
2.5e+00
—
—
—
cases:0.00%
controls:0.64%
—
—
cases:4.59%
controls:0.00%
—
—
cases:7.87%
controls:0.66%
—
—
—
0
7
109
1083
—
5
0
104
1090
—
7
7
82
1053
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
-7.4e-02
4.5e-01
2.5e+00
—
—
8.8e-01
5.0e-01
cases:6.42%
controls:6.88%
cases:8.26%
controls:5.41%
cases:5.50%
controls:0.46%
—
—
—
—
cases:10.11%
controls:4.43%
cases:21.57%
controls:14.25%
7
75
102
1015
9
59
100
1031
6
5
103
1085
—
—
9
47
80
1013
11
118
40
710
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
3.1e-01
1.0e+00
2.5e+00
—
—
6.8e-01
5.3e-01
cases:7.34%
controls:5.50%
cases:11.01%
controls:4.31%
cases:5.50%
controls:0.46%
—
—
—
—
cases:7.87%
controls:4.15%
cases:23.53%
controls:15.34%
8
60
101
1030
12
47
97
1043
6
5
103
1085
—
—
7
44
82
1016
12
127
39
701
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
2.6e-01
1.8e-01
—
—
—
1.4e+00
1.1e+00
cases:11.01%
controls:8.72%
cases:4.59%
controls:3.85%
—
—
—
—
—
—
cases:14.61%
controls:4.06%
cases:29.41%
controls:11.96%
12
95
97
995
5
42
104
1048
—
—
—
13
43
76
1017
15
99
36
729
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.69%
controls:1.69%
—
—
—
—
—
—
8
14
43
814
Spinalanesthesia
WX320 [2001310799]
WX320 [2001310799]
-2.1e-02
—
—
—
—
2.4e+00
1.0e+00
cases:4.59%
controls:4.68%
—
—
—
—
—
—
—
—
cases:12.36%
controls:1.32%
cases:13.73%
controls:5.43%
5
51
104
1039
—
—
—
—
11
14
78
1046
7
45
44
783
Constipation, unspecified
K59.09 [2000502926]
K59.09 [2000502926]
—
2.3e+00
—
—
—
—
—
—
—
cases:4.59%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
5
5
104
1085
—
—
—
—
—
Urinary tract ultrasound examination
KH1AE [2001306329]
KH1AE [2001306329]
1.8e+00
—
—
—
—
—
2.3e+00
cases:4.59%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:1.33%
5
9
104
1081
—
—
—
—
—
6
11
45
817
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
-2.4e-01
—
—
—
—
2.2e+00
1.1e+00
cases:4.59%
controls:5.78%
—
—
—
—
—
—
—
—
cases:12.36%
controls:1.51%
cases:15.69%
controls:5.80%
5
63
104
1027
—
—
—
—
11
16
78
1044
8
48
43
780
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
2.6e-02
6.3e-01
2.1e+00
—
1.6e+00
3.5e-01
6.0e-02
cases:30.28%
controls:29.72%
cases:26.61%
controls:16.24%
cases:15.60%
controls:2.11%
—
—
cases:7.22%
controls:1.47%
cases:21.35%
controls:16.04%
cases:37.25%
controls:35.87%
33
324
76
766
29
177
80
913
17
23
92
1067
—
7
16
90
1072
19
170
70
890
19
297
32
531
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
-1.0e+50
—
—
—
—
2.1e+00
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
cases:6.74%
controls:0.85%
—
—
0
13
109
1077
—
—
—
—
6
9
83
1051
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
—
—
—
—
—
2.1e+00
7.9e-01
—
—
—
—
—
—
—
—
—
—
cases:12.36%
controls:1.70%
cases:11.76%
controls:5.68%
—
—
—
—
—
11
18
78
1042
6
47
45
781
Urinary tract infection, site not specified
N39.0 [45548665]
N39.0 [45548665]
1.5e+00
1.6e+00
—
—
—
2.0e+00
—
cases:7.34%
controls:1.74%
cases:4.59%
controls:0.92%
—
—
—
—
—
—
cases:6.74%
controls:0.94%
—
—
8
19
101
1071
5
10
104
1080
—
—
—
6
10
83
1050
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
—
—
—
1.0e+50
—
2.0e+00
—
—
—
—
—
—
—
cases:5.50%
controls:0.00%
—
—
cases:7.87%
controls:1.13%
—
—
—
—
—
6
0
103
1090
—
7
12
82
1048
—
Cells panel - Urine sediment
58434-2 [40761535]
58434-2 [40761535]
6.1e-01
7.6e-01
—
—
—
1.7e+00
2.0e+00
cases:6.42%
controls:3.58%
cases:4.59%
controls:2.20%
—
—
—
—
—
—
cases:7.87%
controls:1.60%
cases:15.69%
controls:2.54%
7
39
102
1051
5
24
104
1066
—
—
—
7
17
82
1043
8
21
43
807
Actinic keratosis
L57.0 [45591640]
L57.0 [45591640]
2.0e+00
—
—
—
—
—
—
cases:7.34%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
8
12
101
1078
—
—
—
—
—
—
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
—
—
—
1.0e+50
—
1.9e+00
—
—
—
—
—
—
—
cases:5.50%
controls:0.00%
—
—
cases:8.99%
controls:1.42%
—
—
—
—
—
6
0
103
1090
—
8
15
81
1045
—
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
—
—
—
1.0e+50
—
1.9e+00
—
—
—
—
—
—
—
cases:5.50%
controls:0.00%
—
—
cases:8.99%
controls:1.42%
—
—
—
—
—
6
0
103
1090
—
8
15
81
1045
—
pH of Urine by Test strip
5803-2 [3022621]
5803-2 [3022621]
—
1.9e+00
—
—
—
—
—
—
—
cases:6.42%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
7
11
102
1079
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
—
—
—
1.0e+50
—
1.9e+00
1.2e+00
—
—
—
—
—
—
cases:4.59%
controls:0.00%
—
—
cases:8.99%
controls:1.51%
cases:11.76%
controls:3.86%
—
—
—
5
0
104
1090
—
8
16
81
1044
6
32
45
796
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
—
—
—
1.0e+50
—
1.9e+00
—
—
—
—
—
—
—
cases:5.50%
controls:0.00%
—
—
cases:8.99%
controls:1.51%
—
—
—
—
—
6
0
103
1090
—
8
16
81
1044
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
—
—
—
1.0e+50
—
1.9e+00
—
—
—
—
—
—
—
cases:5.50%
controls:0.00%
—
—
cases:8.99%
controls:1.51%
—
—
—
—
—
6
0
103
1090
—
8
16
81
1044
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
—
—
—
1.0e+50
—
1.8e+00
—
—
—
—
—
—
—
cases:5.50%
controls:0.00%
—
—
cases:7.87%
controls:1.32%
—
—
—
—
—
6
0
103
1090
—
7
14
82
1046
—
General Practice
1 [38004446]
1 [38004446]
-2.7e-01
8.2e-01
1.8e+00
—
—
7.8e-01
7.0e-01
cases:16.51%
controls:20.55%
cases:20.18%
controls:10.00%
cases:9.17%
controls:1.56%
—
—
—
—
cases:23.60%
controls:12.45%
cases:41.18%
controls:25.72%
18
224
91
866
22
109
87
981
10
17
99
1073
—
—
21
132
68
928
21
213
30
615
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
—
1.4e+00
—
—
—
—
1.7e+00
—
—
cases:7.34%
controls:1.93%
—
—
—
—
—
—
—
—
cases:19.61%
controls:4.11%
—
8
21
101
1069
—
—
—
—
10
34
41
794
Uroflowmetry
44856007 [4261340]
44856007 [4261340]
6.6e-01
1.5e+00
—
—
—
—
1.7e+00
cases:7.34%
controls:3.94%
cases:5.50%
controls:1.28%
—
—
—
—
—
—
—
—
cases:17.65%
controls:3.74%
8
43
101
1047
6
14
103
1076
—
—
—
—
9
31
42
797
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
3.7e-01
—
—
—
—
1.6e+00
6.4e-01
cases:11.93%
controls:8.53%
—
—
—
—
—
—
—
—
cases:8.99%
controls:1.89%
cases:9.80%
controls:5.43%
13
93
96
997
—
—
—
—
8
20
81
1040
5
45
46
783
Laceration/cut
S18 [2002000983]
S18 [2002000983]
7.1e-01
1.6e-01
—
—
—
1.5e+00
-1.7e-01
cases:20.18%
controls:11.10%
cases:4.59%
controls:3.94%
—
—
—
—
—
—
cases:13.48%
controls:3.40%
cases:11.76%
controls:13.65%
22
121
87
969
5
43
104
1047
—
—
—
12
36
77
1024
6
113
45
715
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:19.61%
controls:5.31%
—
—
—
—
—
—
10
44
41
784
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
-2.1e-01
1.1e+00
—
—
—
1.1e+00
1.4e+00
cases:5.50%
controls:6.70%
cases:5.50%
controls:1.83%
—
—
—
—
—
—
cases:5.62%
controls:1.89%
cases:19.61%
controls:5.43%
6
73
103
1017
6
20
103
1070
—
—
—
5
20
84
1040
10
45
41
783
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
1.2e-02
1.2e+00
—
—
—
8.6e-01
6.2e-01
cases:8.26%
controls:8.17%
cases:12.84%
controls:4.31%
—
—
—
—
—
—
cases:11.24%
controls:5.09%
cases:23.53%
controls:14.25%
9
89
100
1001
14
47
95
1043
—
—
—
10
54
79
1006
12
118
39
710
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
-5.7e-02
8.2e-01
1.8e+00
—
—
1.2e+00
1.8e-01
cases:14.68%
controls:15.41%
cases:17.43%
controls:8.53%
cases:4.59%
controls:0.83%
—
—
—
—
cases:24.72%
controls:9.34%
cases:25.49%
controls:22.22%
16
168
93
922
19
93
90
997
5
9
104
1081
—
—
22
99
67
961
13
184
38
644
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
-1.3e-01
9.1e-01
8.9e-01
—
1.5e+00
1.1e+00
7.0e-01
cases:14.68%
controls:16.33%
cases:17.43%
controls:7.80%
cases:4.59%
controls:1.93%
—
—
cases:7.22%
controls:1.65%
cases:23.60%
controls:9.53%
cases:35.29%
controls:21.26%
16
178
93
912
19
85
90
1005
5
21
104
1069
—
7
18
90
1070
21
101
68
959
18
176
33
652
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
-9.5e-02
5.9e-01
—
1.0e+50
—
1.1e+00
-1.3e-01
cases:12.84%
controls:13.94%
cases:12.84%
controls:7.52%
—
—
cases:6.42%
controls:0.00%
—
—
cases:19.10%
controls:7.55%
cases:17.65%
controls:19.69%
14
152
95
938
14
82
95
1008
—
7
0
102
1090
—
17
80
72
980
9
163
42
665
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
-2.8e-02
1.0e+00
1.1e+00
—
1.1e+00
-2.5e-01
-2.8e-01
cases:26.61%
controls:27.16%
cases:30.28%
controls:13.39%
cases:4.59%
controls:1.65%
—
—
cases:5.15%
controls:1.84%
cases:12.36%
controls:15.38%
cases:27.45%
controls:33.45%
29
296
80
794
33
146
76
944
5
18
104
1072
—
5
20
92
1068
11
163
78
897
14
277
37
551
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
2857-1 [3013603]
-5.0e-02
8.3e-01
—
—
-1.0e+50
-5.4e-01
1.7e-01
cases:20.18%
controls:21.01%
cases:23.85%
controls:12.02%
—
—
—
—
cases:0.00%
controls:1.38%
cases:7.87%
controls:12.83%
cases:29.41%
controls:25.97%
22
229
87
861
26
131
83
959
—
—
0
15
97
1073
7
136
82
924
15
215
36
613
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
-6.1e-01
—
—
—
—
9.8e-03
4.5e-01
cases:5.50%
controls:9.72%
—
—
—
—
—
—
—
—
cases:5.62%
controls:5.57%
cases:11.76%
controls:7.85%
6
106
103
984
—
—
—
—
5
59
84
1001
6
65
45
763
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
—
—
-1.0e+50
—
—
—
1.3e+00
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:9.80%
controls:2.78%
—
—
0
6
109
1084
—
—
—
5
23
46
805
Cystocele
N81.1 [45558171]
N81.1 [45558171]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:0.60%
—
0
5
109
1085
—
—
—
0
7
89
1053
0
5
51
823
Cervicobrachial syndrome
M53.1 [45567577]
M53.1 [45567577]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.97%
—
—
—
—
—
0
5
89
1055
0
8
51
820
Speech therapy
R4130 [2001310235]
R4130 [2001310235]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
5
51
823
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
-3.8e-02
4.3e-01
—
—
—
-5.5e-01
-6.2e-01
cases:13.76%
controls:14.22%
cases:12.84%
controls:8.72%
—
—
—
—
—
—
cases:5.62%
controls:9.34%
cases:13.73%
controls:22.83%
15
155
94
935
14
95
95
995
—
—
—
5
99
84
961
7
189
44
639
Acute maxillary sinusitis
J01.0 [45601112]
J01.0 [45601112]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
0
9
109
1081
—
—
—
0
11
89
1049
—
formoterol and budesonide
R03AK07 [21603281]
R03AK07 [21603281]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:1.32%
cases:0.00%
controls:2.17%
—
0
8
109
1082
—
—
—
0
14
89
1046
0
18
51
810
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
-6.1e-02
4.8e-01
—
—
-1.0e+50
2.8e-01
-6.0e-01
cases:4.59%
controls:4.86%
cases:5.50%
controls:3.49%
—
—
—
—
cases:0.00%
controls:0.46%
cases:6.74%
controls:5.19%
cases:9.80%
controls:16.55%
5
53
104
1037
6
38
103
1052
—
—
0
5
97
1083
6
55
83
1005
5
137
46
691
Sensorineural hearing loss, bilateral
H90.3 [45576850]
H90.3 [45576850]
-1.6e-01
5.6e-01
—
—
—
—
—
cases:7.34%
controls:8.53%
cases:5.50%
controls:3.21%
—
—
—
—
—
—
—
—
—
—
8
93
101
997
6
35
103
1055
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
C01DA14 [21600324]
-7.0e-01
-5.6e-01
-1.0e+50
—
—
—
-1.1e-02
cases:5.50%
controls:10.46%
cases:4.59%
controls:7.80%
cases:0.00%
controls:3.12%
—
—
—
—
—
—
cases:9.80%
controls:9.90%
6
114
103
976
5
85
104
1005
0
34
109
1056
—
—
—
5
82
46
746
Cervical spine X-ray examination without contrast
NA1AA [2001306981]
NA1AA [2001306981]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
erdosteine; oral
R05CB15 [21603394]
R05CB15 [21603394]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.71%
—
0
16
109
1074
—
—
—
—
0
39
51
789
apixaban; oral
B01AF02 [43534762]
B01AF02 [43534762]
—
1.7e-01
—
—
—
3.9e-01
—
—
—
cases:5.50%
controls:4.68%
—
—
—
—
—
—
cases:7.87%
controls:5.47%
—
—
—
6
51
103
1039
—
—
—
7
58
82
1002
—
Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum
17791-5 [3027450]
17791-5 [3027450]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
0
8
109
1082
—
—
—
—
—
0
9
51
819
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
1.5e+00
—
—
—
—
—
1.7e+00
cases:4.59%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:2.42%
5
11
104
1079
—
—
—
—
—
6
20
45
808
Measurement of mechanical axis of lower leg with X-ray
NJ2MA [2001308419]
NJ2MA [2001308419]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.74%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
0
19
109
1071
—
—
—
—
—
0
12
51
816
lovastatin; oral
C10AA02 [21601857]
C10AA02 [21601857]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
10
109
1080
0
6
109
1084
—
—
—
—
0
6
51
822
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
—
—
—
—
—
—
2.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:7.73%
—
—
—
—
—
—
5
64
46
764
Coeliac disease
K90.0 [45586745]
K90.0 [45586745]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Visual field testing with Humphrey automated perimetry
CS434 [2001301476]
CS434 [2001301476]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:1.45%
0
6
109
1084
0
8
109
1082
—
—
—
0
5
89
1055
0
12
51
816
Reticulocyte production index
31111-8 [3000012]
31111-8 [3000012]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Impingement syndrome of shoulder
M75.4 [45553266]
M75.4 [45553266]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
0
7
109
1083
—
—
—
—
—
0
5
51
823
indometacin
C01EB03 [21600365]
C01EB03 [21600365]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.19%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:1.21%
0
13
109
1077
0
6
109
1084
—
—
—
0
5
89
1055
0
10
51
818
Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
35559-4 [3035797]
35559-4 [3035797]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:1.57%
0
12
109
1078
—
—
—
—
0
5
89
1055
0
13
51
815
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
0
5
89
1055
—
Femoral artery PTA
PE1AT [2001309252]
PE1AT [2001309252]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
methenamine; oral
J01XX05 [21603065]
J01XX05 [21603065]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
9
51
819
tramadol and paracetamol
N02AJ13 [1123645]
N02AJ13 [1123645]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
8
51
820
Muscle pain
L18 [2002000642]
L18 [2002000642]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
109
1083
—
—
—
—
—
—
aciclovir
S01AD03 [21603588]
S01AD03 [21603588]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Tobacco use
Z72.0 [45581063]
Z72.0 [45581063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
N03AG01 [21604422]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.28%
cases:0.00%
controls:1.19%
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:1.23%
cases:0.00%
controls:0.97%
0
14
109
1076
0
13
109
1077
0
5
109
1085
—
0
5
97
1083
0
13
89
1047
0
8
51
820
piroxicam; ointment
M02AA07 [21604043]
M02AA07 [21604043]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
0
11
109
1079
—
—
—
—
—
Contusion of shoulder and upper arm
S40.0 [45563774]
S40.0 [45563774]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
CPAP therapy
WX723 [2001310826]
WX723 [2001310826]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
Endovascular dilatation of coronary arteries (PTCA)
FN1AT [2001303062]
FN1AT [2001303062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
Balloon angioplasty and drug eluding stent
AN4 [2000200166]
AN4 [2000200166]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
109
1083
—
—
—
—
—
—
orphenadrine, combinations
M03BC51 [21604113]
M03BC51 [21604113]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:1.09%
—
—
—
—
—
0
5
89
1055
0
9
51
819
Osteoporosis, unspecified
M81.9 [45591963]
M81.9 [45591963]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:1.21%
0
12
109
1078
—
—
—
—
0
5
89
1055
0
10
51
818
Ocular pain
H57.1 [45596140]
H57.1 [45596140]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
5
51
823
Lupus anticoagulant assay
63300003 [4268621]
63300003 [4268621]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
dexamethasone
S01CB01 [21603664]
S01CB01 [21603664]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:1.69%
—
—
—
—
—
0
6
89
1054
0
14
51
814
calcium carbonate
A02AC01 [21600065]
A02AC01 [21600065]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
7
51
821
Insertion of urinary catheter
SPAT1167 [2001700268]
SPAT1167 [2001700268]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
7
51
821
ticagrelor; oral
B01AC24 [40252640]
B01AC24 [40252640]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
0
12
109
1078
0
5
109
1085
—
—
—
—
0
7
51
821
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
4542-7 [3012336]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
0
14
109
1076
—
—
—
—
0
11
89
1049
—
Cathetrisation of artery
TPH07 [2001309747]
TPH07 [2001309747]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:8.26%
controls:0.00%
—
—
—
—
—
—
—
—
—
9
0
100
1090
—
—
—
Periodontitis complex
K05.30 [2000502728]
K05.30 [2000502728]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
0
8
89
1052
—
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2589-0 [3012110]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
109
1080
—
—
—
—
—
—
Cryotherapy
ZXC50 [2001311370]
ZXC50 [2001311370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Geriatric Medicine
38 [38004478]
38 [38004478]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
0
10
109
1080
—
—
—
0
9
89
1051
—
ispaghula (psylla seeds); oral
A06AC01 [21600555]
A06AC01 [21600555]
3.4e-01
—
—
—
—
—
2.9e-01
cases:7.34%
controls:5.32%
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:7.49%
8
58
101
1032
—
—
—
—
—
5
62
46
766
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
-2.7e-01
7.7e-01
—
—
—
3.7e-01
-4.8e-02
cases:11.01%
controls:13.94%
cases:13.76%
controls:6.88%
—
—
—
—
—
—
cases:11.24%
controls:8.02%
cases:17.65%
controls:18.36%
12
152
97
938
15
75
94
1015
—
—
—
10
85
79
975
9
152
42
676
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
SDE03 [2001310351]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
0
8
109
1082
—
—
—
—
—
oxybutynin; oral, transdermal
G04BD04 [21602637]
G04BD04 [21602637]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
0
6
109
1084
—
—
—
—
—
0
5
51
823
dexamethasone
C05AA09 [21601613]
C05AA09 [21601613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.38%
—
—
—
—
—
—
0
28
51
800
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
1.9e-01
7.9e-01
—
—
—
1.2e+00
2.9e-01
cases:9.17%
controls:7.71%
cases:6.42%
controls:3.03%
—
—
—
—
—
—
cases:10.11%
controls:3.40%
cases:13.73%
controls:10.63%
10
84
99
1006
7
33
102
1057
—
—
—
9
36
80
1024
7
88
44
740
salbutamol; inhalant
R03AC02 [21603256]
R03AC02 [21603256]
-1.9e-01
—
—
—
-1.0e+50
1.2e-01
-2.4e-01
cases:12.84%
controls:15.14%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
cases:8.99%
controls:8.02%
cases:13.73%
controls:16.79%
14
165
95
925
—
—
—
0
13
97
1075
8
85
81
975
7
139
44
689
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
290 [2001600222]
-3.9e-01
—
—
—
—
—
—
cases:4.59%
controls:6.61%
—
—
—
—
—
—
—
—
—
—
—
—
5
72
104
1018
—
—
—
—
—
—
Dysphagia
R13 [45573013]
R13 [45573013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
109
1076
—
—
—
—
—
—
Ventricular tachycardia
I47.2 [45586586]
I47.2 [45586586]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
5
109
1085
—
—
—
—
—
0
6
51
822
loratadine; oral
R06AX13 [21603514]
R06AX13 [21603514]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
7
51
821
insulin lispro; parenteral
A10AD04 [21600732]
A10AD04 [21600732]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
Cardiac murmur, unspecified
R01.1 [45548943]
R01.1 [45548943]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
ciclesonide; nasal
R01AD13 [43534836]
R01AD13 [43534836]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.93%
—
—
—
—
—
—
0
16
51
812
Acute conjunctivitis, unspecified
H10.3 [45566958]
H10.3 [45566958]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
7
51
821
Mitral (valve) prolapse
I34.1 [45552788]
I34.1 [45552788]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
0
5
109
1085
—
—
—
—
—
baclofen; oral, parenteral
M03BX01 [21604115]
M03BX01 [21604115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Supraventricular tachycardia
I47.1 [45567178]
I47.1 [45567178]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
0
7
109
1083
—
—
—
—
—
0
7
51
821
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
97097-0 [36033641]
97097-0 [36033641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
Periodontal treatment, very brief
SDA01 [2001310326]
SDA01 [2001310326]
2.6e-01
—
—
—
—
—
—
cases:6.42%
controls:5.05%
—
—
—
—
—
—
—
—
—
—
—
—
7
55
102
1035
—
—
—
—
—
—
Hallux valgus (acquired)
M20.1 [45606152]
M20.1 [45606152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
109
1081
—
—
—
—
—
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
—
1.7e+00
—
—
—
—
—
—
—
cases:5.50%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
6
12
103
1078
—
—
—
—
—
hypromellose
S01KA02 [21605115]
S01KA02 [21605115]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
0
12
89
1048
—
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
OMOP4822009 [45756830]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
10
109
1080
—
—
—
—
—
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
14927-8 [3025839]
—
-1.0e+50
-1.0e+50
—
—
—
-6.6e-01
—
—
cases:0.00%
controls:3.94%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:9.80%
controls:17.39%
—
0
43
109
1047
0
5
109
1085
—
—
—
5
144
46
684
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
2.1e-01
3.1e-01
—
—
—
—
—
cases:4.59%
controls:3.76%
cases:4.59%
controls:3.39%
—
—
—
—
—
—
—
—
—
—
5
41
104
1049
5
37
104
1053
—
—
—
—
—
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
0
6
109
1084
—
—
—
0
9
89
1051
—
tropicamide
S01FA06 [21605065]
S01FA06 [21605065]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
5
51
823
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
WX602 [2001310813]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:7.87%
controls:0.00%
—
—
—
—
—
—
—
7
0
82
1060
—
Stroke/cerebrovascular accident
K90 [2002000617]
K90 [2002000617]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
0
8
109
1082
0
5
109
1085
—
—
—
—
0
9
51
819
Other retinal vascular occlusions
H34.8 [45547863]
H34.8 [45547863]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.85%
—
—
—
—
—
0
5
89
1055
0
7
51
821
sodium fluoride; oral
A01AA01 [21600005]
A01AA01 [21600005]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
10
51
818
Cystoscopy and bladder biopsy
UKC05 [2001306006]
UKC05 [2001306006]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:21.57%
controls:0.00%
—
—
—
—
—
—
11
0
40
828
Dietary counselling and surveillance
Z71.3 [45552101]
Z71.3 [45552101]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
109
1083
—
—
—
—
—
—
dexamethasone
S02BA06 [21605168]
S02BA06 [21605168]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.38%
—
—
—
—
—
—
0
28
51
800
Lumbar spine extensive MRI examination with high intensity magnet
NA3CG [2001307039]
NA3CG [2001307039]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
109
1082
—
—
—
—
—
—
alfacalcidol; oral, parenteral
A11CC03 [21600818]
A11CC03 [21600818]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
8
51
820
loperamide; oral
A07DA03 [21600646]
A07DA03 [21600646]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:1.81%
—
—
—
—
—
—
5
15
46
813
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
K57.3 [45567316]
-1.0e-01
6.8e-01
—
—
-1.0e+50
—
7.8e-01
cases:5.50%
controls:6.06%
cases:4.59%
controls:2.39%
—
—
—
—
cases:0.00%
controls:0.46%
—
—
cases:13.73%
controls:6.76%
6
66
103
1024
5
26
104
1064
—
—
0
5
97
1083
—
7
56
44
772
Eye pressure measurement
XCH00 [2001301234]
XCH00 [2001301234]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
0
14
51
814
Remote monitoring CPAP
WX780 [2001310837]
WX780 [2001310837]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
109
1082
—
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
B01AC04 [21600989]
5.9e-01
—
—
—
-1.0e+50
4.2e-01
3.5e-01
cases:8.26%
controls:4.77%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:5.62%
controls:3.77%
cases:9.80%
controls:7.13%
9
52
100
1038
—
—
—
0
9
97
1079
5
40
84
1020
5
59
46
769
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
1961-2 [3015235]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
0
9
109
1081
0
5
109
1085
—
—
—
—
—
Hypertensive heart disease without (congestive) heart failure
I11.9 [45576863]
I11.9 [45576863]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.85%
0
6
109
1084
—
—
—
—
0
8
89
1052
0
7
51
821
Angina pectoris
I20 [45572078]
I20 [45572078]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
48404-8 [3049804]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
0
10
109
1080
—
—
—
—
—
0
7
51
821
levofloxacin
S01AE05 [43534860]
S01AE05 [43534860]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.74%
—
—
—
—
—
—
cases:0.00%
controls:1.98%
cases:0.00%
controls:4.95%
—
0
19
109
1071
—
—
—
0
21
89
1039
0
41
51
787
glycerol
A06AX01 [21600597]
A06AX01 [21600597]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Bacterial pneumonia, unspecified
J15.9 [45557621]
J15.9 [45557621]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
0
8
109
1082
—
—
—
—
0
13
51
815
Naevus/mole
S82 [2002001046]
S82 [2002001046]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
10
51
818
Diabetic background retinopathy and Type 2 diabetes mellitus, with ophthalmic complications
H36.00*E11.3 [2000503937]
H36.00*E11.3 [2000503937]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
chloramphenicol; ointment
D06AX02 [21602063]
D06AX02 [21602063]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
0
15
51
813
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
30342-0 [3015171]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
109
1079
—
—
—
—
—
—
Recording of ECG
SPAT1097 [2001700198]
SPAT1097 [2001700198]
4.4e-01
—
—
—
—
-1.0e+50
—
cases:6.42%
controls:4.22%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
7
46
102
1044
—
—
—
—
0
10
89
1050
—
Chronic atrial fibrillation
I48.2 [45591467]
I48.2 [45591467]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
0
5
109
1085
—
—
—
—
0
10
89
1050
—
Visual disturbance, unspecified
H53.9 [45557475]
H53.9 [45557475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
Overnight pulse oximetry
252568001 [4091874]
252568001 [4091874]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
5
51
823
Helicobacter pylori Ab [Units/volume] in Serum
7900-4 [3017895]
7900-4 [3017895]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
Sicca syndrome [Sjögren]
M35.0 [45562711]
M35.0 [45562711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
5
51
823
simvastatin; oral
C10AA01 [21601856]
C10AA01 [21601856]
-2.0e-02
-1.9e-01
—
—
—
-4.0e-01
3.2e-01
cases:24.77%
controls:25.14%
cases:17.43%
controls:20.28%
—
—
—
—
—
—
cases:13.48%
controls:18.87%
cases:27.45%
controls:21.50%
27
274
82
816
19
221
90
869
—
—
—
12
200
77
860
14
178
37
650
flucloxacillin; oral, parenteral
J01CF05 [21602857]
J01CF05 [21602857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Malaise and fatigue
R53 [45553741]
R53 [45553741]
—
—
—
—
—
—
1.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:8.82%
—
—
—
—
—
—
5
73
46
755
No disease
A97 [2002000230]
A97 [2002000230]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
8
109
1082
—
0
5
97
1083
—
—
Otolaryngology
4 [38004449]
4 [38004449]
2.6e-01
-3.4e-01
—
—
—
—
6.2e-01
cases:16.51%
controls:13.21%
cases:4.59%
controls:6.33%
—
—
—
—
—
—
—
—
cases:21.57%
controls:12.92%
18
144
91
946
5
69
104
1021
—
—
—
—
11
107
40
721
Other function in accordance with physical therapy nomenclature
SPAT1295 [2001700396]
SPAT1295 [2001700396]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
0
10
109
1080
0
6
109
1084
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
A04 [2002000145]
1.2e+00
—
—
—
—
—
—
cases:6.42%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
—
—
7
22
102
1068
—
—
—
—
—
—
Crystals [Presence] in Synovial fluid by Light microscopy
38458-6 [3050238]
38458-6 [3050238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
7
51
821
Predominantly allergic asthma
J45.0 [45557624]
J45.0 [45557624]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
109
1079
—
—
—
—
—
—
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
S46.0 [45544769]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.57%
0
11
109
1079
—
—
—
—
—
0
13
51
815
General symptom/complaint other
A29 [2002000163]
A29 [2002000163]
7.9e-01
—
—
—
—
—
—
cases:6.42%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
—
7
33
102
1057
—
—
—
—
—
—
Umbilical hernia without obstruction or gangrene
K42.9 [45591589]
K42.9 [45591589]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
-8.2e-02
3.9e-01
—
—
1.6e+00
-4.9e-02
-5.8e-01
cases:24.77%
controls:26.33%
cases:14.68%
controls:10.46%
—
—
—
—
cases:5.15%
controls:1.10%
cases:10.11%
controls:10.57%
cases:13.73%
controls:22.22%
27
287
82
803
16
114
93
976
—
—
5
12
92
1076
9
112
80
948
7
184
44
644
Primary total prosthetic replacement of hip joint not using cement
NFB30 [2001307921]
NFB30 [2001307921]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
0
10
109
1080
0
5
109
1085
—
—
—
—
—
Lumbar epidural anesthesia
WX306 [2001310796]
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
J07BA01 [21601331]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:1.69%
—
—
—
—
—
0
7
89
1053
0
14
51
814
Disorientation, unspecified
R41.0 [45558469]
R41.0 [45558469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
10
51
818
Polymyalgia rheumatica
M35.3 [45533830]
M35.3 [45533830]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.38%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.97%
0
15
109
1075
0
7
109
1083
—
—
—
0
8
89
1052
0
8
51
820
Other specified local infections of skin and subcutaneous tissue
L08.8 [45601211]
L08.8 [45601211]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
5
51
823
Occupational therapy
R4120 [2001310234]
R4120 [2001310234]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
0
6
109
1084
—
—
—
—
—
0
5
51
823
antibiotics in combination with other drugs
S01AA20 [21603571]
S01AA20 [21603571]
-1.6e-01
4.7e-01
—
—
—
—
—
cases:9.17%
controls:10.64%
cases:6.42%
controls:4.13%
—
—
—
—
—
—
—
—
—
—
10
116
99
974
7
45
102
1045
—
—
—
—
—
Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]
I25.0 [45552783]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.83%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:1.04%
cases:0.00%
controls:2.17%
0
20
109
1070
0
8
109
1082
—
—
—
0
11
89
1049
0
18
51
810
Laparoscopic cholangiography
TJK01 [2001305287]
TJK01 [2001305287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
Z01.0 [45566391]
7.6e-01
—
—
—
—
-1.0e+50
-1.0e+50
cases:5.50%
controls:2.66%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.51%
cases:0.00%
controls:4.47%
6
29
103
1061
—
—
—
—
0
16
89
1044
0
37
51
791
Ear pain/earache
H01 [2002000475]
H01 [2002000475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
10
51
818
Contusion of lower back and pelvis
S30.0 [45549279]
S30.0 [45549279]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
0
5
109
1085
—
—
—
—
—
0
5
51
823
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
SPAT1100 [2001700201]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
0
11
51
817
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
NGD05 [2001308109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
109
1080
—
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
SFA30 [2001310360]
6.2e-01
2.1e-01
-1.0e+50
—
-1.0e+50
—
3.0e-02
cases:17.43%
controls:10.18%
cases:4.59%
controls:3.76%
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.55%
—
—
cases:9.80%
controls:9.54%
19
111
90
979
5
41
104
1049
0
5
109
1085
—
0
6
97
1082
—
5
79
46
749
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
3.0e-01
1.3e-01
—
-1.0e+50
—
8.5e-01
—
cases:5.50%
controls:4.13%
cases:4.59%
controls:4.04%
—
—
cases:0.00%
controls:0.55%
—
—
cases:8.99%
controls:4.06%
—
—
6
45
103
1045
5
44
104
1046
—
0
6
109
1084
—
8
43
81
1017
—
Retrograde ureteroscopy
UKB02 [2001305907]
UKB02 [2001305907]
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
cases:4.59%
controls:0.00%
cases:10.09%
controls:0.00%
cases:5.15%
controls:0.00%
cases:14.61%
controls:0.00%
cases:13.73%
controls:0.00%
—
—
5
0
104
1090
11
0
98
1090
5
0
92
1088
13
0
76
1060
7
0
44
828
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
32731-2 [3043747]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:2.17%
0
15
109
1075
—
—
—
—
0
7
89
1053
0
18
51
810
Idiopathic gout
M10.0 [45577131]
M10.0 [45577131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
Pain in throat
R07.0 [45592406]
R07.0 [45592406]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
5
109
1085
—
—
—
—
—
0
6
51
822
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
NA3AA [2001307026]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
7
109
1083
—
—
—
—
—
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
2518-9 [3018405]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
0
7
109
1083
—
—
—
—
0
11
51
817
androstanolone
G03BB02 [21602513]
G03BB02 [21602513]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
7
51
821
Myalgia
M79.1 [45587062]
M79.1 [45587062]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
0
6
109
1084
—
—
—
0
6
89
1054
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
M01AC06 [21603965]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
0
15
89
1045
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
-1.9e-01
8.6e-01
—
—
—
3.5e-01
2.7e-03
cases:11.93%
controls:14.13%
cases:15.60%
controls:7.25%
—
—
—
—
—
—
cases:11.24%
controls:8.21%
cases:19.61%
controls:19.57%
13
154
96
936
17
79
92
1011
—
—
—
10
87
79
973
10
162
41
666
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
-4.2e-01
2.4e-02
1.0e+00
-1.0e+50
—
6.1e-01
3.1e-01
cases:7.34%
controls:10.73%
cases:8.26%
controls:8.07%
cases:7.34%
controls:2.75%
cases:0.00%
controls:1.01%
—
—
cases:14.61%
controls:8.49%
cases:23.53%
controls:18.48%
8
117
101
973
9
88
100
1002
8
30
101
1060
0
11
109
1079
—
13
90
76
970
12
153
39
675
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
-1.4e-01
-8.7e-02
1.4e-02
-1.0e+50
-5.8e-01
-3.3e-01
-4.1e-01
cases:25.69%
controls:28.35%
cases:24.77%
controls:26.42%
cases:7.34%
controls:7.25%
cases:0.00%
controls:0.46%
cases:5.15%
controls:8.82%
cases:22.47%
controls:28.68%
cases:27.45%
controls:36.23%
28
309
81
781
27
288
82
802
8
79
101
1011
0
5
109
1085
5
96
92
992
20
304
69
756
14
300
37
528
Memory test
SPAT1053 [2001700154]
SPAT1053 [2001700154]
-1.8e-01
-1.0e+50
—
—
—
—
—
cases:5.50%
controls:6.51%
cases:0.00%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
6
71
103
1019
0
29
109
1061
—
—
—
—
—
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
346 [2001600307]
346 [2001600307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
0
11
51
817
ofloxacin
S01AE01 [43534856]
S01AE01 [43534856]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
109
1084
—
—
—
—
—
—
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
2.7e-01
3.5e-01
3.4e-01
—
6.0e-01
2.5e-01
4.8e-01
cases:96.33%
controls:95.23%
cases:93.58%
controls:91.10%
cases:68.81%
controls:61.10%
—
—
cases:74.23%
controls:61.31%
cases:94.38%
controls:92.92%
cases:98.04%
controls:96.86%
105
1038
4
52
102
993
7
97
75
666
34
424
—
72
667
25
421
84
985
5
75
50
802
1
26
nifedipine; oral, parenteral
C08CA05 [21601751]
C08CA05 [21601751]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
0
8
109
1082
—
—
—
0
5
89
1055
—
Arthrosis, unspecified
M19.9 [45543488]
M19.9 [45543488]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
0
5
109
1085
—
—
—
—
—
0
9
51
819
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
—
—
—
—
—
1.1e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:6.74%
controls:2.26%
cases:11.76%
controls:3.86%
—
—
—
—
—
6
24
83
1036
6
32
45
796
Inflammatory disease of prostate, unspecified
N41.9 [45539049]
N41.9 [45539049]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
QDB10 [2001309970]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:1.33%
—
—
—
—
—
0
5
89
1055
0
11
51
817
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
A10AC30 [21600727]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
0
9
51
819
carvedilol; oral
C07AG02 [21601700]
C07AG02 [21601700]
1.1e+00
—
—
—
—
—
—
cases:4.59%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
104
1073
—
—
—
—
—
—
Thorax CT examination
GD1AD [2001303618]
GD1AD [2001303618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
109
1082
—
—
—
—
—
—
celiprolol; oral
C07AB08 [21601690]
C07AB08 [21601690]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
0
5
89
1055
—
chloramphenicol
S01AA01 [21603554]
S01AA01 [21603554]
-5.9e-02
—
—
—
—
—
—
cases:8.26%
controls:8.72%
—
—
—
—
—
—
—
—
—
—
—
—
9
95
100
995
—
—
—
—
—
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
—
—
—
—
—
—
2.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:8.09%
—
—
—
—
—
—
5
67
46
761
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
4.5e-01
—
—
—
—
6.8e-01
1.0e-01
cases:5.50%
controls:3.58%
—
—
—
—
—
—
—
—
cases:5.62%
controls:2.92%
cases:11.76%
controls:10.75%
6
39
103
1051
—
—
—
—
5
31
84
1029
6
89
45
739
Dysthymia
F34.1 [45586238]
F34.1 [45586238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
109
1085
—
—
—
—
—
—
Haematemesis
K92.0 [45605964]
K92.0 [45605964]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
6
51
822
Gonarthrosis [arthrosis of knee]
M17 [45601350]
M17 [45601350]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
0
8
89
1052
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
63
265
4.26
12.75
8.1
3.2
0.37
0.40
e6/l
0.06
56
189
74
361
4.27
11.89
4.4
2.4
—
—
estimate
—
0
0
40
142
3.87
9.88
8.6
5.4
105.35
104.11
mmol/l
0.91
40
142
23
54
5.13
9.67
3.3
1.4
5.34
2.97
ug/l
0.51
18
44
77
423
3.79
9.60
11.4
3.9
9.16
12.44
umol/l
4.59
77
395
77
438
3.58
8.77
12.9
5.5
4.21
4.48
e9/l
0.52
64
370
45
191
3.31
8.24
3.4
1.9
—
—
—
0
0
79
478
3.37
7.70
9.1
6.0
1.20
1.21
mmol/l
0.51
72
407
73
454
2.84
6.19
7.3
4.3
0.00
0.00
estimate
-0.00
19
89
31
126
3.04
5.87
5.2
2.6
0.82
0.82
mmol/l
0.02
31
116
71
447
2.69
5.69
7.3
4.3
0.00
0.00
estimate
-0.00
19
84
35
158
2.79
5.45
7.7
3.2
1.25
1.28
e6/l
0.02
26
80
71
458
2.58
5.24
7.5
4.2
0.00
0.05
estimate
0.49
19
83
29
121
2.90
5.19
9.1
6.5
-1.79
1.24
mmol/l
2.62
23
103
19
62
3.50
5.08
11.2
7.7
0.34
0.66
%
4.14
19
62
33
153
2.66
4.82
8.5
3.4
0.72
1.37
e6/l
0.60
25
74
19
67
3.22
4.49
11.3
7.4
0.76
1.37
%
2.60
19
67
21
86
2.79
3.83
5.2
2.5
0.09
0.57
e6/l
2.07
21
80
43
251
2.18
3.64
7.6
4.1
0.00
0.00
estimate
-0.00
14
77
52
338
2.03
3.24
7.7
4.2
0.07
0.00
estimate
0.47
14
63
18
77
2.60
3.01
3.3
2.4
11.48
6.46
umol/l
0.34
18
71
28
150
2.17
2.86
2.4
2.7
9.97
12.73
umol/l
1.44
28
138
39
242
1.95
2.67
7.6
3.6
0.27
0.00
estimate
0.47
11
65
32
185
2.03
2.67
3.1
2.1
2.47
2.43
mmol/l
0.80
26
154
25
137
2.07
2.39
2.4
2.7
1.97
2.20
g/l
0.94
25
124
17
81
2.30
2.27
5.9
1.6
403.47
410.80
nmol/l
0.04
17
74
28
163
1.97
2.27
1.7
1.7
—
—
—
0
0
17
84
2.21
2.09
4.1
2.0
34.76
32.27
u/l
0.18
17
66
26
154
1.90
1.99
1.9
1.6
30.00
29.74
s
0.10
26
147
12
57
2.24
1.62
6.5
7.6
24.10
25.24
mmol/l
0.30
12
57
13
65
2.14
1.56
3.8
2.8
1.80
2.23
mmol/l
—
6
44
5
15
3.44
1.54
1.4
1.7
17.00
76.60
u/ml
—
5
15
13
67
2.07
1.45
10.5
2.1
52.50
52.73
ml/min/173m2
—
6
22
17
97
1.89
1.45
7.1
3.4
—
—
—
0
0
11
53
2.20
1.44
1.2
1.5
—
—
—
0
0
55
436
1.53
1.36
2.0
2.3
98.03
93.59
pmol/l
0.29
30
213
6
24
2.58
1.32
1.3
1.2
—
—
—
0
0
19
118
1.74
1.25
2.6
3.3
5.59
5.76
kpa
0.27
19
113
18
110
1.76
1.25
1.7
1.9
—
—
—
0
0
73
624
1.51
1.20
3.8
4.5
23.19
13.09
mm/h
2.60
68
572
35
260
1.51
1.14
5.6
2.6
37.63
34.65
u/l
0.16
35
245
7
31
2.34
1.12
1.1
1.1
—
79.40
—
0
10
31
228
1.50
1.05
2.1
2.6
358.85
365.31
umol/l
0.10
26
191
0
29
0.00
0.99
0.0
2.0
—
44.70
—
0
23
18
120
1.60
0.92
1.7
1.7
—
—
—
0
0
45
364
1.40
0.92
3.0
4.2
5.83
7.41
mg/mmol
0.36
32
233
11
70
1.64
0.68
1.8
1.4
—
—
—
0
0
10
62
1.67
0.67
2.6
3.6
22.34
24.06
mmol/l
—
10
62
50
430
1.30
0.64
4.6
4.5
1.96
2.11
ug/l
0.10
45
378
81
745
1.34
0.62
5.7
5.4
2.11
1.95
mu/l
0.41
76
661
45
384
1.29
0.60
2.2
2.5
81.70
81.06
nmol/l
0.04
40
334
9
61
1.52
0.55
1.6
2.0
1.98
0.98
%
—
9
61
10
66
1.57
0.54
1.8
1.5
—
—
—
0
0
25
199
1.33
0.54
1.9
1.8
1266.22
1207.62
nmol/l
0.11
20
153
43
370
1.27
0.53
2.0
2.4
—
—
—
0
0
85
794
1.32
0.53
5.7
5.9
6.14
6.15
mmol/l
0.04
77
703
7
106
0.64
0.51
2.6
2.2
1.66
6.03
ug/l
—
7
87
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
5
34
1.49
0.41
1.6
4.8
—
—
—
0
0
10
71
1.45
0.41
1.9
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
78
747
1.16
0.23
4.1
4.7
1.30
1.20
mmol/l
0.64
69
663
34
308
1.15
0.23
1.7
2.2
290.79
225.79
u/l
0.18
34
287
5
42
1.20
0.22
2.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
36
331
1.13
0.19
3.4
4.2
19.95
24.77
%
1.69
19
176
26
236
1.13
0.17
2.1
2.8
0.63
0.78
ug/l
0.58
16
164
18
159
1.16
0.16
1.3
1.2
1.04
1.17
u/ml
—
8
48
6
77
0.77
0.16
1.0
1.3
—
—
—
0
0
10
115
0.86
0.11
12.8
8.2
—
—
—
0
0
63
610
1.08
0.10
4.6
4.2
15.02
15.18
pmol/l
0.20
58
547
80
782
1.09
0.10
8.4
7.8
42.00
40.73
mmol/mol
0.60
75
711
5
45
1.12
0.10
2.0
1.4
—
—
—
0
0
81
800
1.05
0.03
5.3
6.7
2.44
2.49
mmol/l
0.17
76
724
18
187
0.96
0.01
1.6
1.5
1.50
1.43
mg/l
0.05
13
139
79
783
1.03
0.01
4.5
5.6
1.34
1.46
mmol/l
1.38
72
704
12
126
0.95
0.00
3.3
5.2
29.43
32.35
%
—
7
74
79
788
1.01
0.00
4.7
5.7
4.29
4.36
mmol/l
0.21
72
713
0
5
0.00
-0.00
0.0
2.4
—
166.80
—
0
5
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
57
0.87
-0.00
2.6
2.1
12.34
16.63
nmol/l
—
5
51
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
6
62
0.97
-0.00
1.3
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
55.20
—
0
5
0
5
0.00
-0.00
0.0
2.8
—
1.29
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
9.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_URETER – Malignant neoplasm of ureter
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).